Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 109 W. MAIN ST. DALTON OH 44618 |
Tel: | N/A |
Website: | https://www.protokinetix.com |
IR: | See website |
Key People | ||
Clarence E. Smith Chairman of the Board, President, Chief Executive Officer | Michael Richard Guzzetta Chief Financial Officer |
Business Overview |
ProtoKinetix, Incorporated is a research and development stage biotechnology company. The Company is focused on scientific medical research of Anti-Freeze Glycoproteins (AFGPs) or anti-aging glycoproteins. The Company's anti-aging glycopeptide is for ophthalmology, dermatology, transplant support and biomanufacturing. The commercial applications for AAGPs include various health care solutions. In a clinical setting, AAGP is showing its ability to protect cells from inflammation, repair and replace damaged cells and improve cell survivability over time. The Company has not developed a commercially viable product and has not generated any revenue. |
Financial Overview |
For the fiscal year ended 31 December 2023, ProtoKinetix, Inc. revenues was not reported. Net loss decreased 78% to $415K. Lower net loss reflects Share-based compensation decrease from $1.1M (expense) to $0K, Research and development decrease of 75% to $112K (expense), General and administrative decrease of 39% to $100K (expense). |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $6.57M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$0.37M as of Dec 31, 2023 |
Net annual income (TTM): | -$0.42M as of Dec 31, 2023 |
Free cash flow (TTM): | -$0.44M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 346,713,485 as of Mar 20, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |